Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|May 21, 2010
Replication and meta-analysis of 13,000 cases defines the risk for interleukin-23 receptor and autophagy-related 16-like 1 variants in Crohn's diseaseLynn Cotterill, Debbie Payne, Scott Levinson, et al.
European Journal of Gastroenterology & Hepatology|June 17, 2009
Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and IrelandEvangelos A Russo, Marietta Iacucci, James O Lindsay, et al.
RSC Medicinal Chemistry|June 4, 2021
Hit-to-lead optimization of a benzene sulfonamide series for potential antileishmanial agentsPaul J Koovits, Marco A Dessoy, An Matheeussen, et al.
Frontline Gastroenterology|August 26, 2017
Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK: an observational studyCarolynne J Vaizey, Peter R Gibson, Christopher M Black, et al.
European Journal of Medicinal Chemistry|December 2, 2022
Hit-to-lead optimization of a 2-aminobenzimidazole series as new candidates for chagas diseaseCelso de Oliveira Rezende Júnior, Pablo David Grigol Martinez, Rafael Augusto Alves Ferreira, et al.
Plos Neglected Tropical Diseases|February 22, 2021
2-aminobenzimidazoles for leishmaniasis: From initial hit discovery to in vivo profilingRafael Augusto Alves Ferreira, Celso de Oliveira Rezende Junior, Pablo David Grigol Martinez, et al.
Magnetic Resonance Imaging|March 16, 2019
Repeatability and reproducibility of longitudinal relaxation rate in 12 small-animal MRI systemsJohn C Waterton, Catherine D G Hines, Paul D Hockings, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trialCraig Mowat, Ian Arnott, Aiden Cahill, et al.
Journal of Medicinal Chemistry|March 1, 2022
Discovery and Preclinical Pharmacology of INE963, a Potent and Fast-Acting Blood-Stage Antimalarial with a High Barrier to Resistance and Potential for Single-Dose Cures in Uncomplicated MalariaBenjamin R Taft, Fumiaki Yokokawa, Tom Kirrane, et al.
Science Translational Medicine|July 22, 2021
The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to <i>Plasmodium falciparum</i> parasite resistanceJames M Murithi, Cécile Pascal, Jade Bath, et al.
Pageof 4